Advertisement
Screener

Vor Biopharma Inc. (VOR) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3

2.0 / 5 stars · 14/35 Roast Me

Vor Biopharma Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3

Vor Biopharma Inc. (VOR) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.

Financial Statements › Notes › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 · last filed 2026-08-11

  • Vor Biopharma Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for the quarter ending 2026-06-30 was $0.00.
  • Vor Biopharma Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for the quarter ending 2026-03-31 was $0.00.
  • Vor Biopharma Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for the quarter ending 2025-12-31 was $0.00.
  • Vor Biopharma Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for the quarter ending 2025-09-30 was $0.00.
  • Vor Biopharma Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for fiscal 2025 was $0.00.
  • Vor Biopharma Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for fiscal 2024 was $0.00.
  • Vor Biopharma Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for fiscal 2023 was $0.00.
  • Vor Biopharma Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for fiscal 2022 was $0.00.
Period endFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 3 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 6 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 9 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 12 month
2026-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11
$0.00
10-Q · filed 2026-08-11
$0.00
derived: sum of 3 quarters · filed 2026-08-11
$0.00
derived: sum of 4 quarters · filed 2026-08-11
2026-03-31$0.00
10-Q · filed 2026-05-13
$0.00
derived: sum of 2 quarters · filed 2026-05-13
$0.00
derived: sum of 3 quarters · filed 2026-05-13
$0.00
derived: sum of 4 quarters · filed 2026-05-13
2025-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$0.00
derived: sum of 2 quarters · filed 2026-03-30
$0.00
derived: sum of 3 quarters · filed 2026-03-30
$0.00
10-K · filed 2026-03-30
2025-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
$0.00
derived: sum of 2 quarters · filed 2025-11-13
$0.00
10-Q · filed 2025-11-13
$0.00
derived: sum of 4 quarters · filed 2026-03-30
2025-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
$0.00
10-Q · filed 2025-08-12
$0.00
derived: sum of 3 quarters · filed 2026-03-30
$0.00
derived: sum of 4 quarters · filed 2026-03-30
2025-03-31$0.00
10-Q · filed 2025-05-14
$0.00
derived: sum of 2 quarters · filed 2026-03-30
$0.00
derived: sum of 3 quarters · filed 2026-03-30
$0.00
derived: sum of 4 quarters · filed 2026-03-30
2024-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$0.00
derived: sum of 2 quarters · filed 2026-03-30
$0.00
derived: sum of 3 quarters · filed 2026-03-30
$0.00
10-K · filed 2026-03-30
2024-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
$0.00
derived: sum of 2 quarters · filed 2024-11-07
$0.00
10-Q · filed 2024-11-07
$0.00
derived: sum of 4 quarters · filed 2025-03-20
2024-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
$0.00
10-Q · filed 2024-08-08
$0.00
derived: sum of 3 quarters · filed 2025-03-20
$0.00
derived: sum of 4 quarters · filed 2025-03-20
2024-03-31$0.00
10-Q · filed 2024-05-09
$0.00
derived: sum of 2 quarters · filed 2025-03-20
$0.00
derived: sum of 3 quarters · filed 2025-03-20
$0.00
derived: sum of 4 quarters · filed 2025-03-20
2023-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20
$0.00
derived: sum of 2 quarters · filed 2025-03-20
$0.00
derived: sum of 3 quarters · filed 2025-03-20
$0.00
10-K · filed 2025-03-20
2023-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07
$0.00
derived: sum of 2 quarters · filed 2023-11-07
$0.00
10-Q · filed 2023-11-07
$0.00
derived: sum of 4 quarters · filed 2024-03-20
2023-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
$0.00
10-Q · filed 2023-08-10
$0.00
derived: sum of 3 quarters · filed 2024-03-20
$0.00
derived: sum of 4 quarters · filed 2024-03-20
2023-03-31$0.00
10-Q · filed 2023-05-11
$0.00
derived: sum of 2 quarters · filed 2024-03-20
$0.00
derived: sum of 3 quarters · filed 2024-03-20
$0.00
derived: sum of 4 quarters · filed 2024-03-20
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20
$0.00
derived: sum of 2 quarters · filed 2024-03-20
$0.00
derived: sum of 3 quarters · filed 2024-03-20
$0.00
10-K · filed 2024-03-20
2022-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
$0.00
derived: sum of 2 quarters · filed 2022-11-10
$0.00
10-Q · filed 2022-11-10
$0.00
derived: sum of 4 quarters · filed 2023-03-23
2022-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
$0.00
10-Q · filed 2022-08-11
$0.00
derived: sum of 3 quarters · filed 2023-03-23
2022-03-31$0.00
10-Q · filed 2022-05-12
$0.00
derived: sum of 2 quarters · filed 2023-03-23
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23
$0.00
10-K · filed 2023-03-23
2021-09-30$0.00
10-Q · filed 2021-11-10
2021-03-31$0.00
10-Q · filed 2021-05-06
2020-12-31$0.00
10-K · filed 2022-03-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81
Replimune Group, Inc. (REPL)United States$1.186B-3.13
Cullinan Therapeutics, Inc. (CGEM)United States$0.993B-5.72
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
Attovia Therapeutics, Inc. (ATTO)United States$0.828B
Solid Biosciences Inc. (SLDB)United States$0.802B-5.07
4D Molecular Therapeutics, Inc. (FDMT)United States$0.733B-4.10